​

Arbutus Biopharma (ABUS) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ABUS Stock Forecast

Arbutus Biopharma (ABUS) stock forecast, based on 3 Wall Street analysts, predicts a 12-month average price target of $8.50, with a high of $8.50 and a low of $8.50. This represents a 151.48% increase from the last price of $3.38.

$2 $3 $4 $5 $6 $7 $8 $9 High: $8.5 Avg: $8.5 Low: $8.5 Last Closed Price: $3.38

ABUS Stock Rating

Arbutus Biopharma stock's rating consensus is Buy, based on 3 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 3 0 3 Strong Sell Sell Hold Buy Strong Buy

ABUS Forecast vs Benchmarks

TypeNameUpside
StockArbutus Biopharma151.48%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$3.38$3.38$3.38
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25221--5
Dec, 24221--5
Nov, 24241--7
Oct, 24241--7
Sep, 24241--7
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 17, 2022Ed ArceH.C. Wainwright$8.50$3.02181.46%151.48%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 05, 2024JefferiesBuyBuyhold
Jun 28, 2022JMP SecuritiesMarket OutperformMarket Outperformhold
Mar 17, 2022H.C. WainwrightBuyBuyhold
Feb 02, 2022JefferiesBuyupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.86$-0.73$-0.46$-0.44-----
Avg Forecast$-0.98$-0.86$-0.45$-0.44$-0.39$-0.33$-0.41$-0.18$-0.23
High Forecast$-1.21$-1.07$-0.51$-0.45$-0.40$-0.41$-0.46$-0.20$-0.26
Low Forecast$-0.77$-0.68$-0.38$-0.43$-0.38$-0.29$-0.32$-0.14$-0.18
Surprise %-12.24%-15.12%2.22%------

Revenue Forecast

$0 $13M $26M $39M $52M $65M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$6.91M$10.99M$39.02M$18.14M-----
Avg Forecast$6.52M$10.68M$38.96M$20.78M$6.19M$5.19M$8.42M$9.26M$56.41M
High Forecast$5.45M$8.92M$34.07M$20.36M$5.99M$4.97M$8.40M$9.24M$46.88M
Low Forecast$7.72M$12.63M$42.68M$21.03M$6.50M$5.45M$8.43M$9.28M$61.84M
Surprise %5.99%2.93%0.14%-12.71%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-65.21M$-77.35M$-69.46M$-72.85M-----
Avg Forecast$-162.64M$-143.06M$-75.01M$-72.85M$-64.39M$-57.64M$-64.83M$-28.46M$-38.17M
High Forecast$-201.36M$-177.12M$-84.31M$-73.97M$-66.04M$-67.24M$-76.56M$-33.61M$-42.95M
Low Forecast$-127.91M$-112.51M$-62.76M$-70.75M$-62.74M$-48.03M$-53.10M$-23.31M$-29.79M
Surprise %-59.90%-45.93%-7.41%------

ABUS Forecast FAQ

Is Arbutus Biopharma stock a buy?

Arbutus Biopharma stock has a consensus rating of Buy, based on 3 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Arbutus Biopharma is a favorable investment for most analysts.

What is Arbutus Biopharma's price target?

Arbutus Biopharma's price target, set by 3 Wall Street analysts, averages $8.5 over the next 12 months. The price target range spans from $8.5 at the low end to $8.5 at the high end, suggesting a potential 151.48% change from the previous close price of $3.38.

How does Arbutus Biopharma stock forecast compare to the average forecast of its sector, industry, and investment themes?

Arbutus Biopharma stock forecast shows a 151.48% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and outperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Arbutus Biopharma over the past three months?

  • January 2025: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 40.00% Strong Buy, 40.00% Buy, 20.00% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 28.57% Strong Buy, 57.14% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.

What is Arbutus Biopharma’s EPS forecast?

Arbutus Biopharma's average annual EPS forecast for its fiscal year ending in December is -0.39 for 2024, a -11.36% decrease from the reported $-0.44 in 2023. The prediction for 2025 is $-0.33, $-0.41 for 2026, $-0.18 for 2027, and $-0.23 for 2028.

What is Arbutus Biopharma’s revenue forecast?

Arbutus Biopharma's average annual revenue forecast for its fiscal year ending in December is $6.19M for 2024, a -65.89% decrease from the reported $18.14M in 2023. The forecast for 2025 is $5.19M, $8.42M for 2026, $9.26M for 2027, and $56.41M for 2028.

What is Arbutus Biopharma’s net income forecast?

For its fiscal year ending in December, Arbutus Biopharma's average annual net income forecast is $-64.393M for 2024, reflecting a -11.61% decrease from the reported $-72.849M in 2023. The projection for 2025 is $-57.637M, $-64.831M for 2026, $-28.462M for 2027, and $-38.171M for 2028.